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Objective. To establish how real-world evidence (RWE) has been used to inform single tech-
nology appraisals (STAs) of cancer drugs conducted by the National Institute for Health and
Care Excellence (NICE).
Methods. STAs published by NICE from April 2011 to October 2018 that evaluated cancer
treatments were reviewed. Information regarding the use of RWE to directly inform the com-
pany-submitted cost-effectiveness analysis was extracted and categorized by topic. Summary
statistics were used to describe emergent themes, and a narrative summary was provided
for key case studies.
Results. Materials for a total of 113 relevant STAs were identified and analyzed, of which
nearly all (96 percent) included some form of RWE within the company-submitted cost-
effectiveness analysis. The most common categories of RWE use concerned the health-related
quality of life of patients (71 percent), costs (46 percent), and medical resource utilization (40
percent). While sources of RWE were routinely criticized as part of the appraisal process, we
identified only two cases where the use of RWE was overtly rejected; hence, in the majority of
cases, RWE was accepted in cancer drug submissions to NICE.
Discussion. RWE has been used extensively in cancer submissions to NICE. Key criticisms of
RWE in submissions to NICE are seldom regarding the use of RWE in general; instead, these
are typically concerned with specific data sources and the applicability of these to the decision
problem. Within an appropriate context, RWE constitutes an extremely valuable source of
information to inform decision making; yet the development of best practice guidelines
may improve current reporting standards.
Background
Following regulatory approval, a successful reimbursement decision by funding bodies is
required for patient access to new treatments. In England, this body is the National
Institute for Health and Care Excellence (NICE), who publish nationally mandated guidance
regarding the acceptance of new health technologies by the National Health Service (NHS).
Guidance produced by NICE on health technologies is also applied selectively in Northern
Ireland, Scotland, and Wales. Evidence submissions from companies to NICE typically include
analysis of clinical trial data, economic modeling, and the synthesis of other relevant informa-
tion, such as clinical expert opinion and epidemiological data. Since the inception of NICE in
1999, a total of 544 technology appraisals (TAs, as of January 2019) have been published across
a range of different disease areas, of which 240 were of cancer drugs (1).
In this area, when NICE are faced with uncertainty in regards to the clinical- and/or cost-
effectiveness of cancer drugs that may be addressed with further data collection, interim fund-
ing may instead be obtained via the Cancer Drugs Fund (CDF) (2). The CDF was set up in
2011 as a mechanism to improve patient access to cancer drugs, and was reformed in 2016
to ensure further evidence collection as part of managed access agreements to minimize delays
to patient access (3). Additional nontrial data may provide useful information to decision
makers, as it is seldom the case that trials are able to provide all evidence necessary to inform
decision making. This is particularly prevalent in oncology, where treatments for rare cancers
may receive regulatory approval based on data from an uncontrolled (Phase II) trial, which
may lack necessary evidence for health technology assessment (HTA).
Data reflecting the use of a given intervention within a nontrial (or “true-to-life”) clinical
setting are often termed “real-world data” (RWD)— the analysis of which is termed “real-
world evidence” (RWE). The NICE Decision Support Unit (DSU) currently defines RWD
and RWE as:
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0266462320000434
Downloaded from https://www.cambridge.org/core. IP address: 176.253.25.198, on 12 Jan 2021 at 15:46:12, subject to the Cambridge Core terms of use, available at
RWD is a commonly used term to describe data generated from sources
that relate to everyday clinical practice, generally outside the artificial con-
straints of randomized controlled trials. In its broad definition, RWD can
include data generated as part of pragmatic controlled trials, however most
RWD does not produce randomized evidence of treatment effect. In the
context of Health Technology Assessment (HTA), RWD typically presents
as observational data from registries, administrative databases and surveys.
Bell et al. (4).
RWE has the potential to provide useful information regarding
the use and/or outcomes of a given treatment within a setting most
relevant to UK routine practice or to fill in data gaps not addressed
by clinical trials (e.g. informing the underlying nature of a disease
or long-term disease outcomes). However, a number of potential
challenges in the collection of RWE data in NICE appraisals have
been identified including difficulties in collecting baseline health-
related quality of life (HRQoL) data and patient consent, securing
adequate funding to maintain a database and support staff, infor-
mation technology issues, and a lack of a clear control group. In
spite of these challenges, over time RWE has gained increasing
use to inform decision making for reimbursement authorities (4).
Study Objectives
In light of the increasing acceptance and profile of RWE to sup-
port decision making by NICE, this study aims to establish how
RWE has been used to inform NICE appraisals of cancer drugs.
We conducted a review of NICE cancer single technology apprais-
als (STAs) to establish where RWE played a pivotal role in the
decision-making process. To explore RWE more thoroughly, we
identify exemplar cancer STAs for which RWE was integrated
appropriately, and conversely STAs for which RWE were provided
and subject to negative criticism throughout the NICE process by
the independent Evidence Review Group (ERG) and NICE
Appraisal Committee (henceforth termed “the Committee’).
Methods
Identification of Appraisals
Searches were conducted in October 2018 to capture all relevant
STAs published from April 2011 until the search date. April
2011, the data of introduction for the CDF, was the chosen cut-off
for the review as the CDF actively encouraged the collection of
RWE to support NICE decision making. The STAs were identified
by viewing guidance by topic on the NICE Web site, as well as
downloading the relevant material to check for eligibility.
Eligibility Criteria
Completed STAs published by NICE from April 2011 to October
2018 that evaluated pharmacological interventions in populations
with cancer were included within the review. Appraisals for non-
cancer populations were excluded, as well as any terminated
appraisals. Multiple technology appraisals (MTAs) were excluded
as the MTA process does not require companies to submit evi-
dence (though they may choose to do so). Between April 2011
and October 2018, NICE published 39 MTAs across all disease
areas versus 288 STAs (correct as of October 2018). Therefore,
while some relevant information may be reported within MTA
documentation, these appraisals were excluded in the interest of
comparing interventions assessed under the same NICE appraisal
process. In addition, STAs focusing on interventions related to
complications of cancer (as opposed to treatment of cancer specif-
ically) were also excluded. Two reviewers assessed the eligibility of
STAs and cross-checked results before deciding on an agreed list
of relevant studies.
Data Extraction
A data extraction form was developed prior to the identification of
relevant STAs. The data extraction form was designed to capture
data regarding the use of RWE to inform cost-effectiveness mod-
eling. The focus of this study was placed on RWE used in the
company model, given that these inputs will feature in the
calculation of the ICER, and therefore ultimately have an impact
(however small this may be) on decision making. Categories of
RWE use were extracted to establish which aspects of submitted
cost-effectiveness analyses are most frequently supported using
RWE—for example, use of RWE to support the quantification
of costs, patient outcomes, HRQoL, and so on. Other data
extracted included the key source(s) of clinical effectiveness, eco-
nomic model type, and broad comments raised by relevant parties
on the use of RWE. Missing documents (such as earlier iterations
of appraisals that were superseded) were requested from NICE via
email. A second reviewer checked 20 percent of extracted STAs.
For the purpose of this study, RWE was defined as follows:
“analysis of data regarding the health state and/or delivery of
health care collected in a non-interventional trial setting,” which
while simplified is broadly aligned with published definitions
(4;5). The focus of this study was placed upon the use of RWE
to directly inform the company-submitted cost-effectiveness anal-
ysis; therefore, evidence used to support the interpretation and/or
perception of the cost-effectiveness results (but not used to inform
them) was not considered. Analysis of data collected from national
databases that were not specific to a particular clinical indication,
and are used as standard (e.g. national statistics, NHS reference
costs, etc.), was not deemed as relevant RWE.
Synthesis
Across all identified STAs, a summary of the use of RWE was
obtained via the response to the following questions: (1) did the
company provide RWE to support the cost-effectiveness analysis
submitted? (2) if so, was this provided upfront or in response to a
criticism raised throughout the NICE process? and (3) was the use
of RWE submitted by the company ultimately rejected by the
Committee? Where an explicit rejection of the use of RWE was
not provided, it was assumed that the RWE use was accepted.
STA case studies were identified through the data extraction
and discussion with the research team. Case studies were selected
where the use of RWE played a substantial role within the cost-
effectiveness analysis, and was subject to discussion as part of
the NICE process. The final collection of case studies was
designed to cover a range of different treatments, disease areas,
RWE use, and timeframe of assessment. Review findings for the
identified case studies are presented as a narrative summary.
Results
Identified NICE Appraisals
From April 2011 to October 2018, NICE published a total of 288
TAs. Of these, a total of 114 were completed (i.e. nonterminated)
STAs that evaluated pharmacological interventions in populations
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with cancer. Submission dossier material for n = 113 STAs was
available from either the NICE Web site or following a request
sent to NICE. Materials for the missing STA (TA457, carfilzomib
for previously treated multiple myeloma) could not be provided
by NICE at the time of this review due to a potential breach of
confidence (under Section 41 of the Data Protection Act 2018)
(6). The identification of relevant NICE STAs is presented as a
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) diagram in Figure 1 (7).
Generalized Summary of RWE Use
Nearly all assessments (n = 108 of 113, 96 percent) incorporated
some degree of RWE to inform the cost-effectiveness analysis as
part of the STA process (provided in the company’s original sub-
mission dossier). We identified only ten STAs wherein RWE was
found to be provided solely as a direct response to an ERG or
Committee request or criticism; however, in practice, this number
acts as a lower bound as it is possible that RWE may have been
provided in response to documentation not available in the public
domain (e.g. following the decision problem meeting held as part
of the NICE STA process).
A summary of the type of RWE provided as part of the STA
process is presented in Figure 2. The most common types of
RWE presented include analysis relating to the HRQoL of patients
(“Utilities,” n = 80, 71 percent), the costs used to populate the
model (“Costs,” n = 52, 46 percent), and the quantification of
medical resource utilization (“Resource use,” n = 45, 40 percent).
Real-world utility data were primarily sourced from published
studies (n = 72), either related to health state utility values, adverse
event-related utility losses, or age-adjustments incorporated
within the company’s economic model. In a small number of
STAs (n = 8), utilities were obtained from unpublished data (e.g.
company-led data collection), predominantly to inform health
state utility values. The most common cost item cited from
RWE sources was end-of-life care. Resource use frequencies
were typically obtained via chart reviews, registry databases, or
published literature.
Unsurprisingly, there were several instances where specific
source(s) and/or application(s) of RWE were subject to critique
by either the ERG, Committee, or both. For example, the rele-
vance of an identified RWE source to the UK population may
be questionable, or the choice of statistical model applied to the
RWD may be subject to criticism. The phrasing within the final
recommendation for each STA precluded a formal analysis of
RWE source or application acceptance. This is because it is rela-
tively commonplace for the Committee to consider “a range of
scenarios” to inform decision making. To illustrate where the
Figure 1. PRISMA diagram of included NICE STAs. NICE, National Institute for Health and Care Excellence; PRISMA, Preferred Reporting Items for Systematic
Reviews and Meta-Analyses; STA, single technology appraisal.
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use of RWE has been disputed in previous STAs conducted by
NICE, case studies are discussed later in the article.
In only two STAs did the ERG outrightly reject the use of RWE
to inform the estimation of an intervention’s cost-effectiveness—in
both instances, the Committee agreed that RWE presented was
inappropriate to inform the cost-effectiveness analysis. The first
of these was TA523 (midostaurin for untreated acute myeloid leu-
kemia) in which the company used matching to a historical con-
trol (observational data) to inform overall survival estimates in the
economic model, though the pivotal trial for midostaurin was a
randomized controlled trial. The ERG commented that as the his-
torical control study was nonrandomized, it was susceptible to
bias, and as life expectancy had increased in recent years, data
from historical controls were less relevant. The trial-based eco-
nomic model was preferred by the ERG and the Committee.
The second instance of RWE rejection was in TA370 (bortezo-
mib for previously untreated mantle cell lymphoma), where the
company provided end-of-life costs based on a sample of forty
patients. The ERG opted to remove this cost from the economic
model entirely as it was considered to be taken from a small
and heterogeneous population, and included costs for
not-for-profit and nongovernmental healthcare organizations
(beyond the scope of costs considered by NICE). The
Committee agreed with the removal of these costs.
Case Studies
Four case studies were identified to highlight a range of RWE
usage in company submissions to NICE. The case study STAs
were chosen to reflect a number of different types of cancer, sub-
mitting companies, dates of assessment, nature of RWE use, and
perception by the ERG and Committee. Table 1 summarizes the
included case studies.
Discussion
RWE has been used in a multitude of applications to inform
healthcare decision making by NICE, particularly in the field of
oncology where clinical trials often do not provide all evidence
required to inform cost-effectiveness analysis (though these issues
are by no means unique to studies conducted in cancer). The
CDF was introduced to facilitate RWD collection to reduce uncer-
tainty and inform decision making, thus the focus of our review
was to consider how RWE has factored into NICE appraisals of
cancer treatments. This study illustrates how RWE has been
used by companies to support the submission of cost-effectiveness
evidence to NICE and highlights typical uses via the presentation
of case studies. Compared with clinical trial data, RWE may be
considered a better representation of local patient demographics,
more reflective of clinical practice, and potentially be closer
aligned with contemporary treatment patterns.
The key criticisms around RWE sources are typically con-
cerned with the comparability of real-world patient cohorts to
the clinical trial patients, and how relevant RWE patient cohorts
are to contemporary practice (4;18). This is in addition to the
commonly recognized concerns around bias when interpreting
evidence collected outside of a controlled (trial) setting. We
only identified two STAs where RWE was rejected in its entirety
(i.e. both the source and approach were considered inappropriate
for decision making). Instead, it was much more commonplace
for the ERG and/or Committee to dispute the specific source(s)
or application(s) of RWE provided (but not both simultaneously).
Nevertheless, RWE has been shown to have a clear role in
decision making, by addressing data gaps in cost-effectiveness
analyses submitted by companies, and ultimately being used to
inform the decision made (through impacting the estimate of
the ICER).
Figure 2. Use of real-world evidence by category. Admin, administration; AE, adverse event; RWE, real-world evidence; STA, single technology appraisal.
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Table 1. Case Studies of RWE Use in NICE Appraisals
Appraisal Data gap
Company approach






The company presented survival
extrapolations using data from the
Surveillance, Epidemiology, and End Results
(SEER) registry to inform modeled hazard of
death beyond duration of clinical trial
follow-up period (8). Utility values from a
standard gamble study were also used (9)
While the Committee accepted the idea of using
external evidence to support decision making,
each of the preferred sources was disputed by
the ERG and Committee. More specifically, data
from an observational study by Balch et al. (10)
were preferred over the SEER registry data as
the Balch data allowed for adjustment
according to staging of disease, and utility
values from another study were preferred over
the standard gamble study (10;11)
Check for alternative RWE sources, in
particular where alternative analytical
approaches may be taken across different
sources (e.g. matching). Ensure alignment of






The company included findings from a chart
review to quantify the costs associated with
best supportive care, and a costing study of
UK patients receiving palliative care to
capture the costs incurred by patients
towards the end of life (12). The company
also conducted a survey to establish
real-world treatment patterns in order to
determine relevant comparator treatments
used in UK clinical practice
The costing studies were accepted as
appropriate for informing decision making.
However, the ERG commented that the survey
regarding treatment patterns was based on
data from June to July 2013 (FAD published in
November 2015); and that since this time
favorable results from another clinical study of
currently used docetaxel (COUGAR II) may have
led to increased real-world use of taxanes in
general. The ERG undertook a number of
analyses to incorporate comparators excluded
by the company on the basis of this survey,
which was considered to be outdated
Assess the relevance of historical RWE to
current practice, especially when there has
been published documentation that may
influence treatment patterns. If changes have







The company conducted retrospective
observational studies for patients treated
with chemotherapy in order to facilitate a
comparison with the pivotal single-arm trial
of avelumab (13;14). A study of end-of-life
cancer care was cited to inform the cost of
terminal care (15)
The ERG and Committee criticized the methods
used to analyze the data from the observational
studies, requesting the use of matching
methods to adjust for differences in patient
characteristics and noting the retrospective
design which may lead to date of publication
bias. However, the Committee ultimately
accepted RWE based on the observational data
to inform decision making. The end-of-life care
costs were also deemed appropriate
Where possible, proactively undertake
matching analyses to address any potential
imbalances in baseline patient characteristics






The company provided evidence from a
number of sources to inform the uptake and
outcomes of patients who bridge from the
treatment to a potentially curative
autologous stem cell transplant (ASCT), the
main efficacy driver in this appraisal,
including data collected on real-world UK
patients while brentuximab vedotin was
made available via the CDF (16;17)
The ERG and Committee stated concerns
regarding the use of observational data to
inform the cost-effectiveness analysis, but
noted that these data were more reflective of
UK practice versus clinical trial data, and were
in agreement with the economic modeling
presented. To the authors’ knowledge, TA524
represents the first appraisal conducted by NICE
where the clinical evidence base considered by
the Committee comprised entirely of RWE and
other nontrial-based published material
Provide an in-depth explanation of the
generalizability of the RWE, particularly when
being used in preference to clinical trial data.
Clarify why trial-based analyses should not be
preferred over RWE (if relevant)




























bridge.org/core. IP address: 176.253.25.198, on 12 Jan 2021 at 15:46:12, subject to the Cam
bridge Core term
s of use, available at
Previous studies regarding RWE use to support NICE decision
making have either considered a holistic view of the STA process,
or have adopted a relatively narrow perspective as to what consti-
tutes RWE (4;18–21). One of these studies is the NICE DSU
report (4) which presents a comprehensive overview of RWE
use in submissions to NICE across a range of therapeutic areas;
including available NICE method manuals, methodological tech-
niques to analyze RWD, and opinions on the application of RWE
to the STA process from NICE personnel (4). The DSU report
provides a useful source of information concerning the general
use of RWE, yet is not specific to the issues that typically afflict
cancer trials (only one cancer case study is noted within the
DSU report: TA401, bosutinib for previously treated chronic mye-
loid leukemia) (4). The DSU report calls for the development of
guidelines on the application of appropriate statistical methods
to RWE, and highlights that current guidance across NICE pro-
grams is somewhat misaligned in relation to the discussion of
RWE.
Makady et al. (21) considered the use of RWE to inform a
range of HTA reports across five European agencies within the
context of treatments for patients with melanoma. The authors
of this study found that RWE had been predominantly used to
estimate epidemiological information (such as prevalence), long-
term effectiveness (i.e. survival), and quantify drug-related costs,
though these findings were based on a limited number of
melanoma-based case studies.
In our study, NICE STAs of cancer treatments were systemati-
cally identified and carefully searched for the specific use(s) of
RWE to inform the submitted cost-effectiveness analysis. A
large number of relevant STAs were identified, and several of
these were subject to multiple rounds of evidence submission,
meetings, and (where relevant) appeals. The sheer volume of
materials necessitated a degree of interpretation as to which opin-
ions may be taken to be reflective of the Committee’s final deci-
sion (e.g. where a preliminary recommendation discussed a
topic which was not included within the final recommendation).
The need to differentiate between opinions that may be consid-
ered “interim” or “final” is not specific to the use of RWE, but
is notably relevant to our study as perceptions of RWE may
have changed over time.
It should be noted that the definition of RWD (and conse-
quently, RWE) differs across studies, and so the findings of our
review should be interpreted with this in mind. Some studies con-
sider data from single-arm clinical trials as RWD, though this
does not align with the majority of published definitions (4;5).
It is the view of the authors that RWE should not be collected
within a controlled, clinical trial setting—if evidence collected in
this way were considered RWE, the same could be said by looking
at results from individual arms of controlled trials. Our review
does not consider the interpretation of different evidence types
(of which RWE is one specific type), and so some of the findings
may indeed apply to other types of evidence. In addition, our
study relies upon accurate reporting in NICE appraisal documen-
tation, and so a degree of subjectivity with regards to determining
RWE sources was required.
In our study, we focused on the use of RWE to inform the
company’s cost-effectiveness analysis only, and in doing so were
able to illustrate how this evidence has informed NICE appraisals
of cancer drugs. Through reviewing published NICE appraisals,
we intended to illustrate how RWE has been used to inform con-
temporary HTA decision making. However, the use of RWE may
feature more broadly to contextualize and/or lend support to the
findings of the economic evaluation. It is often the case that com-
panies provide or refer to RWE to support the claim that a given
intervention meets NICE’s end-of-life criteria (i.e. that survival
expectancy with current care is <2 years). Use of RWE in this
manner does not influence the model results per se, but may
have a profound influence on the interpretation of analyses,
and thus impact the final decision made by the Committee.
Further research is needed to explore more broad usage of
RWE in submissions to NICE outside of the submitted economic
evaluation.
A further limitation of this study was the reliance upon pub-
lished materials. Materials were requested from NICE, but it
was only possible to review those that were obtainable by the
authors. For instance, it was not possible to review any RWE
obtained via the CDF that was not presented in the public domain
or any data provided to the ERG that were unreported or heavily
redacted; as well as information for the missing STA (TA457,
which NICE was unable to share). Furthermore, the determina-
tion of RWE sources is subject to the description of data collec-
tion provided within the relevant studies—some of which were
unpublished and therefore it could not be ascertained with abso-
lute certainty whether the sources aligned with the definition of
RWE used in our study. The NICE STA process is recognized
as one of the most transparent in the field of HTA, yet the con-
fidentiality and/or opacity of some information submitted as
part of the STA process precludes a fully exhaustive review of
all evidence presented to the Committee, and thus establishes
with greater certainty the type(s) and/or quality of data consid-
ered acceptable.
Our review provides an overview of the key criticisms raised by
NICE that should be addressed prior to submission—for example,
providing a clear justification of the similarities between the piv-
otal trial population and patients considered within the RWE. By
addressing RWE criticisms commonly raised throughout the STA
process upfront, the ability for the Committee to make decisions
in a timely manner may be improved, thus limiting the extent to
which patient access may be delayed. While our study focuses on
submissions for cancer drugs, the findings of our study may be
useful more broadly wherever RWE is utilized. The development
of HTA-focused guidance regarding the appropriate use of RWE
may also improve the usefulness of the evidence submission by
companies to the Committee. Through improved presentation
of evidence, a clearer understanding of common themes regarding
the acceptance and rejection of RWE may be ascertained. Such
guidance may be improved through collaboration with regulatory
bodies for whom guidelines have previously been developed (5).
In June 2019, NICE announced its “statement of intent” con-
cerning the potential for an increasing use of health and social
care data to inform guidance development (22). This document
explains NICE’s wish to expand its methods and processes to
enable more extensive and effective use of broader sources of
data, such as RWE, to inform its decision making. Outside of
NICE, various other initiatives have been developed to incorpo-
rate the use of RWE into decision making. For example, in
Australia, the melanoma drug ipilimumab (Yervoy®, Bristol
Myers-Squibb) was conditionally recommended by the
Pharmaceutical Benefits Advisory Committee (PBAC) provided
2-year overall survival outcomes observed in practice aligned
with the pivotal clinical trial (23). From 2018, the Scottish
Medicines Consortium (SMC) are now able to make interim deci-
sions for medicines that have been given a conditional marketing
authorization by the European Medicines Agency (EMA), subject
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to ongoing evaluation and future reassessment (24). The future
role of RWE in HTA decision making relating to cancer drugs,
both in the UK and internationally, is expected to increase over
time based on relatively recent changes to the mechanisms
under which interventions are able to be assessed and recom-
mended for practice. This research may serve as a useful source
of information for those involved in establishing how RWE may
be used in HTA assessments.
In conclusion, our review found the use of RWE in NICE sub-
missions of cancer drugs to be extensive, and in general appears to
have provided a valuable source of information to aid decision
making. Common criticisms of RWE were related to specific
sources or analytical methods, though the use of RWE in general
was rarely rejected in its entirety. Where possible we recommend
that submissions to NICE should aim to proactively acknowledge
these common criticisms, through clear justification of the
approaches taken to analyze RWE and the relevance of the
RWD source, which may be aided by the development of best
practice guidelines for reporting standards of RWD and its appli-
cation as RWE.
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